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To overcome the drug resistance phenomenon induced by Imatibib (IM), in clinical practice, are often used second generation of tyrosine
kinase inhibitors as Nilotinib (NIL); a such potent inhibitor of the BCR/ABL kinase and Dasatinib (DAS), a inhibitor of BCR/ABL kinase, and
inhibitor SrC family kinase. In this study we evaluated the in vivo effect of DAS, NIL, and IM on intracellular calcium concentration, oxidative
stress, and apoptosis in peripheral blood leukocytes of 45 newly diagnosed patients with chronic myeloid leukaemia (CML-PBM). Our data
demonstrated that treatment with DAS and NIL showed an higher modulating potential than IM on intracellular calcium concentration by
inhibiting the thapsigargin, a sarcoplasmic/endoplasmic reticulum Ca2þ-ATPase (SERCA) inhibitor, and Lithium (Li) an inositol 1,4,5-
triphosphate (InsP3) receptor inhibitor activities. Moreover our data demonstrated that NIL and DAS have signiﬁcantly increased
apoptosis more than IM by involving both intracellular calcium signaling as well as oxidative stress. The acquisition of the oxidative stress
and calcium channels receptors values data could help the hematologist to modulate and improve the treatment of chronic myeloid
leukaemia (CML) pathology.
J. Cell. Physiol. 231: 680–687, 2016.  2015 Wiley Periodicals, Inc.
Chronic myeloid leukaemia (CML) is a myeloproliferative disease
that originates in an haemopoietic stem cell as the result of the t
(9;22) translocation, giving rise to the Philadelphia chromosome
and bcr-abl oncoprotein p210bcr-abl. The BCR-ABL chimeric
protein is thought to play a central role in the pathogenesis of Ph
chromosome-positive leukaemia (Sawyers, 1999). Since several
years, for the treatment of CML speciﬁc inhibitors of BRC/ABL
protein kinase are employed. The ﬁrst inhibitor usedwas imatinib
mesylate (IM), a small-molecule tyrosine kinase inhibitor, which
binds to anATP-binding site on BCR-ABL, KIT, PDGF-R, andABL
protein-tyrosine kinase, thus preventing downstream signaling. In
humans, this drughas been successfully usedas a therapeutic agent
for Philadelphia-positive chronic myeloid leukemia and
gastrointestinal stromal tumor carrying a c-KIT mutation
(Demetri et al., 2002). In veterinarymedicine, clinical studies have
reported that IM is effective against canine mast cell tumors
carrying the ITD mutation on c-KIT in exon 8 or 11 and the
c.1523A>Tmutation inexon9 (Kobayashi et al., 2013).However,
IM is ineffective in treating cases of patients with mutations in
some kinase domains (Y253F/H; E255K/V; T315I; H396P/R43,44;
M244V; M351T o F359V) that confer high resistance to
pharmacological treatment for which is need to increase the daily
dose to be administered (Hochhaus and La Rosee, 2007). To
overcome the drug resistance phenomenon, since several years,
in clinical practice, second generation of tyrosine kinase inhibitors
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(TKI) widely such as (NIL), a potent inhibitor of the BCR/ABL
kinase structurally similar to IM, was rationally designed to
improve binding afﬁnity against BCR-ABL and improve speciﬁcity
over that of IM (Weisberg et al., 2005) and (DAS), a potent
inhibitor of BCR/ABL kinase (Shah et al., 2004) and inhibitor SrC
family kinase, c-kit, and platelet-derived growth factor receptor
(Lombardo et al., 2004). Several studies demonstrated a
correlation between the activity of TKI, and alteration of
intracellular calcium homeostasis. In fact the alteration in the
ionized calcium concentration in the cytosol has been implicated
in the initiation of secretion, contraction, and cell proliferation
(Kretsinger, 1979) as well as the production of reactive oxygen
species (ROS), natural by-products of aerobic metabolism, has
been correlated with normal cell proliferation through activation
of growth-related signalling pathways (Murrell et al., 1990). High
concentration of intracellular ROS provides a direct effector
mechanism for necrotic cell death and a mild increase in ROS,
either H2O2 or O2
 prooxidant state that could provide
protection against apoptosis (Pervaiz et al., 2001). By contrast, an
H2O2/O
2 ratio that favors reduction of the intracellular milieu,
reduced state, sensitizes cells to apoptotic triggers that could
eventually lead to spontaneous apoptosis (Clement et al., 1998).
Finally theproductionofROShasbeencorrelateswithnormal cell
proliferation through activation of growth-related signaling
pathways (Murrell et al., 1990). Moreover to ROS have been
ascribed a role as signallingmolecules in immunity, basing inter alia
on the ﬁndings that lymphocyte effector cells such as natural killer
and cytotoxic T cells undergo apoptosis-like cell death after
encounter with ROS-producing myeloid cells (Thoren et al.,
2007). Recently, studies by Bellodi et al. (2009) showed in primary
CML and K562 cells that in vitro treatment with IM induce
apoptosis through inhibition of BCR/ABL protein and also
through inhibition of the calcium release from the intracellular
stores induced by thapsigargin. Some TKI can induce apoptosis
inducing a sustained increase in concentration of intracellular
Ca2þ resulting from depletion of the endoplasmic reticulumCa2þ
stores (Sergeev, 2004). In agreement with these results, recently,
we demonstrated that functionality of calcium channel and
oxidative stress on CML lymphomonocytes are dramatically
compromised (Ciarcia et al., 2010) and that IM, in vitro, in K562
and CML cells, exerts its activity after modulation of intracellular
calcium concentration (Ciarcia et al., 2013). Therefore is evident
the ability of TKI to use more pathways to exert their
pharmacological activity. The aimof this studywas to compare the
in vivo effect of NIL or DAS or IM in peripheral blood
mononuclear cells of patients with (CML-PBM) on the
mobilization of intracellular calcium, oxidative stress and
apoptosis in order to verify some aspects of the signalling
cascades.
Materials and Methods
Patients
For this study n. 45 volunteers patients with CML (21 males and 24
females; mean age 56 years; range 45–61 years), after obtaining
informed consent, were selected and processed at the time of
diagnosis and after oral treatment for 6 months with NIL at dose of
600mg/die or DAS at dose of 100mg/die or IM at dose of 400mg/
die. Eligible patients have been diagnosed with PhþCML-CP
(Cytogenetic analysis showed that Ph chromosome were 100% of
positive). Chronic phase was deﬁned by the presence of <15%
blasts,<20% basophils, and<30% blasts plus promyelocytes in the
peripheral blood or bone marrow.
Chemicals
(NIL) and Imatinib mesylate (IM) were kindly provided from
Novartis SpA (Novartis Internation AG CH-4002 Basel
Switzerland); (DAS) was provided by Bristol-Myers Squibb Srl (UK
AP invoicing, Chester CH1 9LE UK); RPMI-1640 was purchased
from Labtek Laboratories, Eurobio, Paris, France; Lithium chloride
(Li), Thapsigargin (TG), Inositol 1,4,5-triphosphate (InsP3),
phitoemoagglutinine (PHA), foetal calf serum (FCS), hystopaque,
propidium iodide (PI), were obtained from SIGMA (Milan, Italy).
Leukocytes preparation
Peripheral blood mononuclear cells of healthy subjects
(CS-PBM) or untreated CML patients (basal CML-PBM) or
treated CML patients with DAS or IM or NIL were isolated using
the modiﬁcation of a method of Boyum as described by Bass et al.
(1978); 15–20ml human blood, obtained from volunteers healthy
donors or CML patients, was drawn in heparin (20U/ml), stratiﬁed
on Ficoll-Hystopaque gradients (density 1.077), and centrifuged for
30min at 600g. The ring of leukocytes at the interface was
collected and washed two times with 5ml of PBS. The preparation
was found to be 89% pure by ﬂow cytometric analysis (range 82–
93%; red blood cells 6.3%; polymorphonucleates 2.6%; platelets
2.3%). Lymphocytes were washed by centrifugation for 5min at
600g and re-suspended in RPMI 1640 supplemented with 10% fetal
calf serum (FCS), 1% penicillin and streptomycin, 2mM glutamine.
Aliquots of lympho-monocytes were incubated for 1 hour in
humidiﬁed atmosphere of 5%CO2 at 37°C in culture plastic plates.
Light microscopy and ﬂow cytoﬂuorimetric analysis of stained cells
demonstrated that more than 96 2% of the adherent cells were
monocytes. Viable lymphomonocytes (as evaluated by means of
the trypan blue exclusion test) were seeded at 3 106 cells in 6-
well tissue culture plates and cultured overnight in RPMI 1640
complete medium.
CCyR assay
Complete Cytogenetic Response (CCyR) was performed by
chromosome banding analysis (CBA) after short-term 24h. Brieﬂy,
Bone marrow aspiration for cytogenetic analysis were treated with
colchicine and hypotonic solution, then they were centrifuged, and
the resulting pellet was ﬁxed and washed in methanol/acetic acid
(3:1). The cells were resuspended in ﬁxative and dropped on slides.
Karyotypes of samples were examined after the G banding
technique and described according to International System for
Human Cytogenetic Nomenclature (ISCN 1995) (Wei et al., 1995).
MMR assay
The molecular monitoring was based on peripheral blood samples
collected before therapy and after treatment for 6months. BCR-ABL
transcripts level assessment was performed by real-time quantitative
polymerase chain reaction (RT-Q-PCR) according to suggested
procedures and recommendations (Hughes et al., 2006). The
Molecular Response was deﬁned as Major (MMR) if the BCR-ABL/
ABL ratio was 0.1% according to the International Scale (Branford
et al., 2008).
Intracellular calcium measurement
Intracellular Ca2þ concentrations [Ca2þ]i were measured by using
the radiometric ﬂuorescent indicator dye FURA-2/AM, the
membrane-permeant form of FURA-2/AM as previously described
and opportunely modiﬁed (Florio et al., 2003). Brieﬂy, CS-PBM or
CML-PBM cells were washed twice in PBS in 15ml polypropylene
tubes (Falcon/Becton Dickinson Labware, Lincoln Park, NJ)
resuspended in Krebs Ringer (KRH) medium (1 106 cells/ml)
with 3.0mM Ca2þ-sensitive dye FURA-2/AM for 60min at 30°C.
We also added the non ionic detergent Pluronic acid F-127
(0.02%w/v) to each incubation batch as a dispersing agent. Cell
were subsequently centrifuged and resuspended in KRH calcium
free or containing 1mMCaCl2. The samples were then transferred
to a thermostat-equipped cuvette (37°C), maintained under
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continuous stirring and analyzed in a SPEX
spectrophotoﬂuorimeter (two wavelengths excitations, 340 and
380 nm and emission intensities at 515 nm). The experiments were
initiated by incubation of cell aliquots (1 106 cells) with several
drugs for 5min. After stimulation with thapsigargin (TG) or
inositol 1,4,5-triphosphate (InsP3), the recording was continued
until the end of the [Ca2þ]i peak. At the end of the experiment
calibration was performed determining minimal ﬂuorescence
induced by 0.1% triton X – 100 in presence of 5mM EGTA (Fmin)
and maximal ﬂuorescence induced by 3mM CaCl2 (Fmax).
Intracellular calcium concentration was calculated according to the
method of Grinkiewicz et al., to the equation:
[Ca2þ]i¼ 224 [(RRmin)/RmaxR)] were R is the
experimentally determined ﬂuorescence ratio (Grynkiewicz et al.,
1985).
Malondialdheyde assay
Lipid peroxidation as index of the oxidative stress was determined
by assaying the Malondialdheyde (MDA) production by means of
the thiobarbituric acid test (TBA test) (Esterbauer and
Cheeseman, 1990). Brieﬂy: 1mL of suspension of peripheral blood
mononuclear cells (PMB cells) containing 1 106 cells treated or
non treated for 24 h with 3mM TG or 10mM Li was mixed with
0.5ml of cold 30% (w/v) trichloroacetic acid to precipitate
proteins. The precipitate was pelletted by centrifugation and 1ml
of the supernatant was reacted with 1.3mL of 0.5% (w/v)
thiobarbituric acid (TBA) at 85°C for 40min. In TBA test reaction,
one molecule of MDA reacts with two molecules of TBA with the
production of a pink pigment. Therefore, after cooling, the
ﬂuorescence of pigment was read at excitation of 536 nm and
emission of 557 nm wavelengths in a SPEX Fluoromax
spectrophotoﬂuorimeter. The concentration of MDA was
calculated respect to a calibration curve (range: 0.5–2 pmol/ml),
and results were expressed as pmol of MDA/mg proteins.
SOD assay
Superoxide dismutase (SOD) activity was determined by sensitive
SOD assay that utilizes a product a water-soluble formazan dye
upon reduction with superoxide anion SOD Activity with
absorbance at 450 nm according to themanufacturer’s instructions
(Assay Kit Fluka Products). Brieﬂy, 1ml of PBM cells containing
1 106 cells treatedor not treated for 24 hwith 3mMTGor10mM
Li was mixed. At the end of incubation cells were lysed and
centrifuged at 14,000g for 5min at 4°C and on cytosol was
determined cytosolic and mitochondrial SOD activity. The starter
of reaction by adding Xanthine Solution. The absorbance readings
every minute for 10min at room temperature. The rate of the
reduction with a superoxide anion is linearly related to the xanthine
oxidase (XO) activity, and is inhibited by SOD.TheSODactivitywas
expressed as % of inhibition respect to activity Control. One unit of
SODactivitywas deﬁned as the amount of enzyme required for 50%
inhibition of NBT reduction in the assay conditions. The SOD levels
were expressed as units/mg proteins.
Apoptosis assay
Apoptosis was also evaluated with a cell death ELISA kit
(Boehringer Mannheim, Indianapolis, IN) which utilizes a
monoclonal antibody against histone to detect DNA fragments in
the cytosolic fraction of lysed cells. Cells treated or untreated
were lysed according to the manufacturer’s instructions. The
samples were transferred into 96-well dishes coated with a mouse
monoclonal antibody against histone. After incubation and
washing, anti-DNA-peroxidase was added to the wells. Cell
culture supernatants removed from the cells after treatment (but
before lysis) gave no signal, indicating that there were no necrotic
cells during the treatment. The reaction was developed with the
substrate supplied by the manufacturer and the absorbance of the
wells was read at 410 nm and results expressed as absorbance of
oligonucleosomes (O.D.).
Total protein assay
Total proteins were determined by the method of Lowry et al.
(1951).
Statistical analysis
Data are expressed as mean standard deviation of four
independent determinations. An error probability with P< 0.05
(including P< 0.01 and P< 0.001) was selected as signiﬁcant. All
experiments were performed in duplicate and the mean was used
for analysis.
Results
Efﬁcacy
Data related to the rate of CCyR and MMR in CML patients
treated for 6 months with TKI are shown in Table 1. CCyR was
achieved in 77% of patients treatedwithDAS, in 87% of patients
treated with NIL and in 65% of patients treated with IM. The
corresponding MMR rates were of 69% (DAS), 73% (NIL) and
53% (IM).
DAS, IM, and NIL inhibit calcium mobilization in-
duced by TG or InsP3. It’s known that the BCR/ABL–
expressing cells show impaired ER homeostasis and are unable
to activate ER calcium-mediated apoptotic pathways (Keeshan
et al., 2002). Thus we investigated the in vivo effect of three
different TK inhibitor on [Ca2þ]i in CML cells. In Figure 1 are
shown the results obtained by using increasing concentrations
(range 0–20mM) of InsP3 on the mobilization intracellular
calcium. PBM cells obtained from healthy patients (CS-PBM) or
CML patients untreated (basal CML) or treated with DAS, IM
and NIL, as described in MM, were loaded with FURA-2/AM
and balanced for 10min in a calcium-free medium for
determination of InsP3 activity. InsP3 signiﬁcantly reduced the
mobilization of [Ca2þ]i in a dose dependent manner with an
IC50 of 4.6 0.52mM (basal CML-PBM cells) respect to
3.3 0.29mM (CS-PBM cells) (P< 0.05). The treatment of
patients with the inhibitors induced a signiﬁcantly reduction
(P< 0.05) of InsP3 activity. In fact the IC50 shifted from
4.6 0.52mM (basal CML-PBM cells) to 8.4 0.78 (82,6%),
7.3 0.71 (58.7%) or 10.1 0.93mM (119.6%) for DAS, IM,
and NIL respectively.
In Panel (A) are reported the results obtained on the
intracellular calcium mobilization induced by 5mM InsP3. The
treatment with DAS, IM, and NIL reduced signiﬁcantly
(P< 0.05) the intracellular calcium mobilization induced by
InsP3 of 47.5 5.2, 30.3 2.9 and of 56.2 6.7% respectively.
In Figure 2 are shown the results obtained by using increasing
concentrations (range 0–30mM)ofTG, a speciﬁc inhibitor of the
SERCA channels, on the intracellular calciummobilization. PBM
cells of healthy subjects (CS-PBM) or CML patients untreated
(basal CML) or treatedwithDAS, IM, andNIL, were loadedwith
FURA-2/AM and balanced for 10min in a calcium-free medium
for the determination of TG activity. TG signiﬁcantly reduced
TABLE 1. Cytogenetic and molecular response in treated CML patients
Drugs Patients CCyR (%) MMR (%)
NIL 15 13 (87) 11 (73)
IM 17 11 (65) 9 (53)
Complete Cytogenetic Response (CCyR) and Major Molecular Response (MMR) in CML
patients treated for 6 months with DAS, NIL, or IM.
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the mobilization of [Ca2þ]i in a dose dependent manner whit on
IC50 of 5.1 0.55 (basal CML-PBM cells) respect to
3,7 0.28mM (CS-PBM cells) (P< 0.05). The treatment of
patients with DAS, IM and NIL induced a signiﬁcant reduction
(P< 0.05) of TG activity. In fact the IC50 shifted from
5.1 0.55mM (basal CML-PBM cells) to 9.6 0.83, 7.1 0.66
or 14.4 1.2mM for DAS, IM and NIL respectively.
In Panel (A) are reported the results obtained on the
intracellular calcium mobilization induced by 3mM TG. The
treatment with DAS, IM and NIL reduced signiﬁcantly
(P< 0.05) the intracellular calcium mobilization induced by TG
of 44.7 3.9, 26.4 2.7 and of 57.9 5.5% respectively.
Activity of DAS, IM, and NIL on MDA and SOD
levels. We evaluated the production of MDA, a reliable
marker of oxidative stress (Rossi et al., 2006) as well as the
SOD activity to verify a possible correlation between induction
of oxidative stress and inositol triphosphate receptor (IP3R) or
SERCA signalling cascades we using the TG (speciﬁc inhibitor of
the SERCA channels) and the Lithium chloride (Li) (a regulator
of the levels of inositol-1,4,5-trisphosphate and inhibitor of
InsP3 receptors).
The Figure 3 show the results obtained in healthy subjects
(Control) and in CML-PBM cells before (basal CML) or after
treatment with DAS, IM and NIL on MDA levels. 106 PBM cells
were incubated for 24 h alone or in presence of 10mMLi or 3mM
di TG. The levels of MDA in basal CML were signiﬁcantly
increased respect Control cells (209.3 19.4 vs.
122.7 21.1 pmol of MDA/mg of protein) (P< 0.05 vs. control
cells). The addiction of TG induced an increase of intracellular
levels of MDA in CML cells and MDA values shifted to
275.3 23.5 pmol of MDA/mg of proteins (P< 0.05 versus basal
CML). The addiction of Li induced a signiﬁcant increase of MDA
levels in CML cells and values shifting 259.7 22.8 pmol of MDA/
mg of proteins (P< 0.05 versus basal CML). The CML-PBM cells
of patients treated with DAS, IM and NIL show higher levels of
MDA respect to basal CML shifting from 209.3 19.4 to
306.1 28.7 or 264.5 21.8 or 345.8 31.4 pmol ofMDA/mgof
proteins respectively. The in vitro administration of TG further
increased the MDA levels to 364.3 29.3 or 318.9 30.9 or
412.5 33.8 pmol of MDA/mg of proteins for DAS, IM and NIL
respectively. Finally the addiction of Li increased the MDA values
to 343.1 34.7 (in CML-DAS) or 307.8 27.6 (in CML-IM) or
395.3 34.1 (in CML-NIL) pmol of MDA/mg of proteins.
The Figure 4 show the results obtained in PBM cells from
healthy subjects (Control) and CML-PBM cells before (basal
CML) e after treatment with DAS, IM, and NIL on SOD activity.
106CML-PBMcellswere incubated for 24 h aloneor in presence
of 10mM Li or 3mM di TG. SOD activity compared to Control
cells markedly decreased in the CML-PBM cells (34.6 3.3 vs.
54.5 6.1U/mg proteins, P< 0.05). The addiction of TG to
CML-PBM cells reduced the SOD activity from 34.6 3.3 to
24.8 2.1 (P< 0.05 vs. basal CML). The addiction of Li in CML-
PBM cells also reduced the SOD activity decreasing from
34.6 3.3 to 26.1 2.3U/mg proteins (P< 0.05 vs. basal CML).
The in vivo treatment with DAS, IM, and NIL signiﬁcantly
reduced SOD activity in CML-PBM cells from 34.6 3.3 to
25.3 2.2 or 28.1 3.1 or 20.3 2.1, respectively. The in vitro
administration of TG further reduced the SOD activity to
17.3 1.9 or 20.4 2.3 or 13.7 1.4U/mg proteins. Finally the
addiction of Li reduced the SOD activity to 19.4 1.6 or
22.9 2.4 or 16.8 1.8 for DAS, IM, and NIL, respectively.
TG and Li increase DAS, IM, and NIL-induced apop-
tosis. The apoptotic activity was evaluated in CML-PBM cells
of patients newly diagnosed (basal CML) and after treatment
with DAS, IM and NIL. 106 CML-PBM cells were incubated for
24 h alone or addition of 3mM di TG. As show Figure 5 in
Fig. 1. In vitro activity of InsP3 on calcium levels in PBM cells obtained from healthy subjects (CS-PBM) or CML patients before (basal CML)
or after treatment with DAS, IM, and NIL. 106 cells were incubated with increasing concentrations (0–20mM) of InsP3 in KRH medium
calcium free. Data represent the [Ca2þ]i values obtained after addition InsP3 (meanS. D.) obtained in four distinct experiments performed
in duplicate. (P< 0.05 vs. CS-PBM;  P< 0.05 vs. basal CML). In Panel A show the percentage variation respect to basal CML of 5mM InsP3 on
calcium levels in untreated or treated CML-PBM cells. (P< 0.05 vs. CML-InsP3).
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untreatedCML-PBM cells theO.D. was 0.02 0.0018 (without
TG) and 0.11 0.08 (with TG). The treatment of patients with
DAS, IM, and NIL induced apoptosis in CML-PBM cells with
O.D. values of 0.07 0.004, 0.050 0.008 and 0.080 0.011
respectively. The addition in vitro of TG determined a
signiﬁcant increase of apoptotic activity in CML-PBM cells of
patients treated with DAS, IM and NIL. In fact O.D. values
shifted from 0.11 0.08 (basal CMLþTG) to 0.170 0.02
(54.5%), 0.130 0.012 (18.2%) and 0.210 0.028 (90.9%) for
DAS, IM, and NIL, respectively.
The Figure 6 show the results obtained using Li on apoptosis.
The apoptotic activity was evaluated in CML-PBM cells before
and after treatment with DAS, IM, and NIL. 106 CML-PBM cells
were incubated for 24 h alone or after addiction 10mM Li. The
CML showed basal levels of O.D. of 0.02 0.0018 (without Li)
and of 0.06 0.009 (with Li). The treatment with DAS, IM and
NIL induced apoptosis in CML-PBM cells with O.D. values of
0.05 0.004, 0.050 0.008, and 0.080 0.010, respectively. In
vitro addition of Li determined a signiﬁcant increase of apoptotic
activity also in CML-PBM cells of patients treated with DAS, IM
and NIL. In fact the O.D. shifted from 0.06 0.009 (basal
CMLþ Li) to 0.140 0.015(133.3%), 0.120 0.016 (100%), and
0.235 0.021 (291.3%) for DAS, IM, and NIL, respectively.
Discussion
The IM administered at 400mg daily, is the standard front-
line therapy for patients with CML (Kantarjian et al., 2002).
Unfortunately several studies have demonstrated that only
the 82% of patients achieved a CCyR (Jabbour et al., 2008)
and a substantial fraction of patients develops acquired
resistance to IM (Hochhaus, 2006). To this end, several
authors investigated the effects of new strategies in front-line
treatment with the second-generation TKI, DAS, and NIL
(Cortes et al., 2010). Our clinical data, reported in Table 1,
conﬁrmed that treatment with DAS, NIL was more effective
respected at IM. It has been demonstrated that the
endoplasmic reticulum (ER) plays an important role in the
regulation of proliferation and apoptosis (Morishima et al.,
2002) and high and low Bcr-Abl–expressing cells, show
impaired ER homeostasis and are unable to activate ER
calcium-mediated apoptotic pathways (Keeshan et al., 2002).
The release of Ca2þ induced by InsP3 from internal Ca
2þ
stores represents one of the most powerful intracellular
signals within the eukaryotic cell (Camello-Almaraz et al.,
2006). It has been demonstrated that TG increase cytosolic
Ca2þ concentrations by blocking SERCA calcium pumping
and produce ER stress by exerting effects on Ca2þ-
dependent chaperones and ROS, releasing of Ca2þ from ER
stores (Rogers et al., 1995). Our recent studies have
demonstrated in CML cells a lower activity of TG and InsP3-
dependent release of calcium from stores as well as a
decreased function of purinergic dependent calcium channels
(Ciarcia et al., 2010). The data presented herein (Figs. 1 and
2) show that treatment with DAS and NIL desensitize more
the SERCA and InsP3 receptors respect to IM in CML-PBM
cells. Moreover, the in vitro addition of 3mM TG or 10mM Li
has induced, in CML cells treated in vivo with NIL and DAS, a
Fig. 2. In vitro activity of TG on calcium levels (CS-PBM) or CML patients before (basal CML) or after treatment with DAS, IM and NIL.
106 cells were incubated with increasing concentrations (0–20mM) of TG in KRH medium calcium free. Data represent the [Ca2þ]i values
obtained after addition TG (meanS. D.) obtained in four distinct experiments performed in duplicate. ( P< 0.05 vs. CS-PBM;  P< 0.05 vs.
basal CML). In Panel A show the percentage variation respect to basal CML of 3mM TG on calcium levels in untreated or treated CML-PBM
cells. (P< 0.05 vs. CML-TG).
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signiﬁcantly lesser effect than in CML cells treated with IM on
[Ca2þ]i. In an in vitro experiment on primary CML cells,
Bellodi et al. (2009) showed that IM induce apoptosis by
inhibition of BCR/ABL protein as wells as through inhibition
of the thapsigargin-induced calcium release (Hughes et al.,
2006). The oscillation of cytosolic Ca2þ concentration is a
potent activator of the intrinsic apoptotic pathway.
Disruption of Ca2þ homeostasis induces a series of
biochemical alterations leading to caspase activation and
subsequent cellular apoptosis (Hajnoczky et al., 2003).
Fig. 3. In vitro effect of TG or Li on MDA levels in PBM cells obtained from healthy subjects (control) or in CML-PBM cells of patients
untreated (Basal CML) or after treatment with DAS, NIL, or IM. 106 of CML-PBM cells incubated for 24h alone or in association with 2mMTG
at 37°C in humidified atmosphere of 5% carbon dioxide in air. Data represents mean of MDA levels expressed in pmoles/mg proteinsS.D.
obtained in four distinct experiments performed in duplicate. (P< 0.05 vs. Control; P< 0.05 vs. basal CML; °P< 0.05 vs. CMLþTG;
°°P< 0.05 vs. CMLþLi.
Fig. 4. In vitro effect of TG or Li on SOD activity in PBM cells obtained from healthy subjects (control) or in CML-PBM cells of patients
untreated (basal CML) or after treatment with DAS, NIL or IM. 106 of CML-PBM cells incubated for 24h alone or in association with 10mM of
Li at 37°C in humidified atmosphere of 5% carbon dioxide in air. Data represents mean of SOD activity expressed in U/mg proteinsS.D.
obtained in four distinct experiments performed in duplicate. (P< 0.05 vs. Control; P< 0.05 vs. basal CML; °P< 0.05 vs. CMLþTG;
°°P< 0.05 vs. CMLþLi.
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Recently studies by Li et al. (2014) have demonstrated, in
human umbilical vein endothelial cells, that intracellular
oxidative stress induced by heat leads to apoptosis triggering
caspases 3 and 9 through pathways mediated by intracellular
calcium and ROS. The role of ROS in carcinogenesis as well
as in apoptosis has been widely documented (Jackson and
Loeb, 2001; Jabs, 1999). It is known that cancer cells
presented an oxidative stress higher compared to the
corresponding healthy cells and that the increase of
intracellular ROS is controlled by antioxidant enzymes
including SOD and Glutathione (Dickinson and Forman,
2002). The manipulation of the altered state, with both
oxidants that with pro-oxidants was often used by
researchers to kill cancer cells (Ho et al., 2011). In fact, an
inhibition of the cellular antioxidant activity leads to
increased ROS levels that, in turn, are able to trigger the
activation of signalling pathways, which could make cancer
cells susceptible to toxic insults (Gao et al., 2012; Chen et al.,
2006). Many anticancer drugs, including C2 ceramide, anti-
IgM antibody and dexamethasone, induce apoptosis through
the stimulation of ROS and accumulation of H2O2 while
many inhibitors of apoptosis have antioxidant properties
(Buttke and Sandstrom, 1994). Recently studies by
Chakraborty et al. (2012) have shown that hydroxychavicol, a
potent inhibitor of xanthine oxidase, puriﬁed from Piper
betle leaves or prepared synthetically is able to induce
apoptosis in K562 and CML cells by activation of JN-kinase
ROS-dependent and revert drug resistance induced by IM. In
our previous research we have demonstrated that in vitro
administration an PI3K tyrosine kinase inhibitor (LY294002)
and an Src kinase inhibitor (PP1) interacts in synergistic
manner with IM to induce apoptosis and autophagy in CML
and K562 cells (Ciarcia et al., 2013). In the present study (ﬁgs.
3, 4, 5, and 6) we showed that treatment with NIL and DAS
increased oxidative stress as well as apoptosis while
decreasing SOD activity more than IM. The in vivo activity of
DAS, NIL, and IM on receptors SERCA and InsP3 and on ROS
seems to support the hypothesis that these inhibitors induce
apoptosis involved both the calcium channels pathways and
oxidative stress. It, is reasonable to hypothize that the
greater activity of NIL respect to IM can be correlated to its
higher afﬁnity versus BCR/ABL kinase receptors while the
greater activity of DAS was due to its activity both on the
BCR/ABL kinase as well as on the SrC kinase receptors. From
our results it can be concluded that, in clinical practice, the
data acquisition of oxidative stress and of calcium channels
receptors in CML-PBM cells induced by TKI could help the
hematologist to modulate therapy in CML.
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Fig. 5. In vitro effect of TG on levels of oligonucleosomes in CML-PBM cells of patients untreated or after treatment with DAS, NIL or IM.
106 of CML-PBM cells were incubated for 24h alone or in association at 2mM TG at 37°C in humidified atmosphere of 5% carbon dioxide in air.
Data represents mean of Absorbance (O.D.)S.D. obtained in four distinct experiments performed in duplicate. (P< 0.05 vs. untreated
CML; P< 0.05 versus Untreated CMLþTG).
Fig. 6. In vitro effect of Li on levels of oligonucleosomes in CML-
PBM cells of patients untreated or after treatment with DAS, NIL,
or IM. 106 of CML-PBM cells were incubated for 24h alone or in
association at 10mM of Li at 37°C in humidified atmosphere of 5%
carbon dioxide in air. Data represents mean of Absorbance
(O. D.)S.D. obtained in four distinct experiments performed in
duplicate. (P< 0.05 vs. untreated CML; P< 0.05 vs. Untreated
CMLþLi).
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